Interpreting interest in interferon-α by Thibault, Donna L & Utz, Paul J
246 DC = dendritic cell; ds = double-stranded; IFN = interferon; PBL = peripheral blood lymphocyte; SLE = systemic lupus erythematosus.
Arthritis Research & Therapy    Vol 5 No 5 Thibault and Utz
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease that affects approximately 0.1% of the
population, with most afflicted individuals being young
women. SLE is characterized by inflammatory destruction
of skin, blood elements, joints, kidneys, serosa, central
nervous system, and other tissues [1]. Despite intensive
efforts by many investigators, the cellular and molecular
mechanisms governing inflammation in connective tissue
diseases such as SLE remain uncertain, although
cytokines are believed to play an important role.
The group of cytokines known as interferons was first
characterized in 1957. Interferons were named for their
ability to ‘interfere’ with viral replication, conferring resis-
tance to infection transferred from virally infected chick
cells into uninfected cells [2]. The therapeutic potential of
interferon in viral infection was first demonstrated through
its ability to inhibit respiratory virus infection [3]. Interfer-
ons have since been proven clinically effective antiviral
and antineoplastic therapeutic agents for a variety of disor-
ders (for review [4]).
There are two groups of interferons: type I interferons
(IFN-α, IFN-β, IFN-ω) and type II interferon (IFN-γ). Human
IFN-α was cloned in 1980, and was found to represent a
mixture of several closely related proteins expressed from
distinct genes [5]. A second type of interferon, IFN-β, is
produced mainly by fibroblasts, is a single protein species,
and was cloned around the same time [6]. A third species
of human type I interferon is known as IFN-ω [7]. IFN-γ is
produced by activated T cells and has been found to be a
single protein in all animal species [8]. Induction of inter-
feron synthesis at high levels is triggered by viruses, and is
also induced by a variety of nonviral agents such as bacte-
ria and synthetic polymers [9,10]. The production of IFN-α
and IFN-β by virally infected cells induces resistance to
viral replication, enhances MHC class I expression,
increases antigen presentation, and activates natural killer
cells to kill virus-infected cells [11]. Thus, type I interferons
are active in both innate and adaptive immunity. The
actions of IFN-γ include macrophage activation, increased
expression of MHC and antigen processing components,
immunoglobulin class switching, and suppression of
T-helper-2 responses [11].
Many historical studies have indicated a role for the type I
interferon system in both human and murine SLE.
Although controversial, some studies have shown that
serum derived from lupus patients contains elevated levels
of IFN-α [12,13]. The levels of IFN-α in serum correlate
with disease severity, as measured by the number of
organs involved and the presence of anti-DNA antibodies
[12,14]. Additionally, the role of IFN-α as a causative
agent in the pathogenesis of SLE is suggested by the
finding that patients who are treated with IFN-α for disor-
ders such as chronic hepatitis C infection and malignancy
occasionally develop antinuclear antibodies, anti-double-
stranded (ds)DNA, and autoimmune disorders [15–18].
The recent studies described below have added signifi-
cantly to this body of literature, strongly implicating IFN-α
and IFN-α inducible proteins as potential targets of thera-
peutics and diagnostics, respectively, in SLE.
A study conducted by Blanco and colleagues [19] has
shown that serum derived from patients with SLE has
the ability to induce the differentiation of monocytes into
dendritic cells (DCs). The induction of DC differentia-
tion was dependent on IFN-α, as demonstrated by addi-
tion of IFN-α to autologous serum (which induced
differentiation into DCs) and addition of IFN-α neutraliz-
ing antibodies to SLE serum (which prevented differen-
tiation into DCs). Monocytes that had been cultured
with SLE sera developed the capacity to process and
present antigens derived from apoptotic cells to CD4+
T lymphocytes. The report concluded that SLE is char-
acterized by a major defect in DC homeostasis, and that
IFN-α is likely to be the main cytokine contributing to
this defect.
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Second, it has been shown that the serum of SLE patients
contains a factor that has the ability to induce the produc-
tion of IFN-α in normal blood leukocytes in vitro [20]. Sub-
sequently, this interferon inducing factor was identified as
small immune complexes. Immune complexes containing
anti-dsDNA antibodies and immunostimulatory plasmid
DNA in combination acted as potent inducers of IFN-α in
natural interferon-producing cells [21]. Priming natural
interferon-producing cells with type I interferons and gran-
ulocyte macrophage-colony stimulating factor greatly
enhanced the ability of these complexes to induce the pro-
duction of IFN-α. This study suggests that IFN-α works
through a positive feedback loop in SLE, mediated by
immune complexes containing anti-DNA antibodies and
DNA.
In a third report [22], expression profiling of peripheral
blood lymphocytes (PBLs) derived from C57BL/6 mice
congenic for the Nba2 non-MHC lupus susceptibility
locus identified only two differentially expressed genes,
both of which were induced by interferon. These inter-
feron-inducible proteins, termed Ifi202 and Ifi203, were
upregulated both at the mRNA and at the protein level in
splenocytes. Two other murine studies have recently
examined the effect of genomic deletion of one of the type
I interferon receptor (IFNAR) chains on disease manifesta-
tions in lupus models [23,24]. Both studies demonstrated
that interferon signaling plays a significant role in the gen-
eration of autoantibodies directed against red blood cells
and DNA, and in mediating renal pathology.
More recently, two studies used DNA microarray technol-
ogy to profile mRNA transcripts from PBLs obtained from
SLE patients. Baechler and colleagues [25] performed
transcript profiling of PBLs from 48 different SLE patients
and 42 healthy control individuals. A ‘biosignature’ was
identified that accurately differentiated between these two
groups. A striking finding in this study was the observation
that many of the upregulated transcripts in PBLs from SLE
patients encoded interferon-inducible proteins. A correla-
tion was found between the number of SLE criteria (partic-
ularly central nervous system and renal disease) and the
number of interferon-inducible transcripts. In the second
study, Bennett and colleagues [26] noted that interferon-
inducible genes, as well as granulopoiesis-related genes,
were overexpressed in blood leukocytes of patients with
active lupus. Importantly, a correlation between disease
activity according to the SLE Disease Activity Index and the
expression of 10 of these genes was demonstrated. This
‘interferon signature’ disappeared when patients were
treated with glucocorticoids. Interestingly, a similar result in
pediatric dermatomyositis was obtained when transcript
profiles from muscle biopsies were analyzed [27].
In summary, IFN-α probably plays an important role in the
pathogenesis of connective tissue diseases such as der-
matomyositis and SLE. The studies described above raise
several important questions for future experiments. What
cells are the main source of IFN-α, and what are the trig-
gers that lead to its secretion? Are there other stimuli in
target cells that can bypass the need for IFN-α, ultimately
triggering the synthesis of IFN-α inducible genes? Can
interferon-inducible gene or protein expression serve as a
biosignature that can be used to categorize patients, to
guide clinical decision making, or to follow patients
enrolled in clinical trials? Finally, can development of
inhibitors of IFN-α signaling effectively treat patients with
connective tissue diseases? In humans, the type I interfer-
ons consist of 14 subtypes of IFN-α, IFN-β, and IFN-ω,
arguing that development of specific therapeutics that can
target all of the relevant type I interferons may be difficult.
Nevertheless, it has been over 25 years since a new thera-
peutic agent for SLE was approved by the US Food and
Drug Administration. Our ‘interpretation’ of the ‘interest in
interferons’ is that disruption of type I interferon signaling
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